| Name | Evixapodlin |
| Description | Evixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities. |
| In vitro | Evixapodlin exhibits an ability to increase the production of IFN-γ and Granzyme B in both CD8+ and CD4+ T cells in individuals with chronic hepatitis B (CHB). Additionally, Evixapodlin enhances the frequency of Granzyme B-positive cells among HBV-specific CD8+ and CD4+ T cells.[1] |
| In vivo | Evixapodlin (10-50 mg/kg; intraperitoneal injection, daily, for 6 days) treatment results in over 90% occupancy of the PD-L1 target on tumor cells. Evixapodlin effectively suppresses tumor growth in a mouse colorectal tumor model (MC38) that expresses human PD-L1.[1] |
| Storage | Store at low temperature,Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (2.89 mM), Sonication is recommended.
10% DMSO+90% Saline : 7.5 mg/mL (10.84 mM), Suspension.
DMSO : 75 mg/mL (108.44 mM), Sonication is recommended.
|
| Keywords | PD-L1 | PDL1 | PD-1/PD-L1 | PD1/PDL1 | PD-1 | PD1 | HBV | GS4224 | GS 4224 | Evixapodlin | Antiviral |
| Inhibitors Related | Dibenzofuran | Esculin | Doxorubicin hydrochloride | Hexane-2,5-dione | Lamivudine | Cetylpyridinium Chloride | Tenofovir Disoproxil Fumarate | Sodium formate | Thiamine hydrochloride | (Tetrahydro-2H-pyran-4-yl)methanol | Nicotinamide | Tenofovir |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
